Shortly after entering the cell, HIV-1 copies its genomic RNA into double-stranded DNA in a process known as reverse transcription. This process starts inside a core consisting of an enclosed lattice of capsid proteins that protect the viral RNA from cytosolic sensors and degradation pathways. To accomplish reverse transcription and integrate cDNA into the host cell genome, the capsid shell needs to be disassembled, or uncoated. Premature or delayed uncoating attenuates reverse transcription and blocks HIV-1 infectivity. Small molecules that bind to the capsid lattice of the HIV-1 core and either destabilize or stabilize its structure could thus function as effective HIV-1 inhibitors. To screen for such compounds, we modified our recently developed FAITH assay to allow direct assessment of the stability of in vitro preassembled HIV-1 capsid-nucleocapsid (CANC) tubular particles. This new assay is a high-throughput fluorescence method based on measuring the amount of nucleic acid released from CANC complexes under disassembly conditions. The amount of disassembled CANC particles and released nucleic acid is proportional to the fluorescence signal, from which the relative percentage of CANC stability can be calculated. We consider our assay a potentially powerful tool for in vitro screening for compounds that alter HIV disassembly.

Department of Biochemistry and Microbiology University of Chemistry and Technology Prague 166 28 Prague Czech Republic

Department of Biotechnology University of Chemistry and Technology Prague 166 28 Czech Republic

Department of Chemistry of Natural Compounds University of Chemistry and Technology Prague 166 28 Prague Czech Republic

Institute of Organic Chemistry and Biochemistry IOCB Research Centre and Gilead Sciences Academy of Sciences of the Czech Republic Flemingovo nám 2 166 10 Prague Czech Republic

NMR Laboratory University of Chemistry and Technology Prague 166 28 Prague Czech Republic

Zobrazit více v PubMed

Yamauchi Y, Greber UF. Principles of Virus Uncoating: Cues and the Snooker Ball. Traffic. 2016;17:569–592. doi: 10.1111/tra.12387. PubMed DOI PMC

Bhargava A, Lahaye X, Manel N. Let me in: Control of HIV nuclear entry at the nuclear envelope. Cytokine Growth Factor Rev. 2018;40:59–67. doi: 10.1016/j.cytogfr.2018.02.006. PubMed DOI

Kilcher S, Mercer J. DNA virus uncoating. Virology. 2015;479:578–590. doi: 10.1016/j.virol.2015.01.024. PubMed DOI

Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 1994;372:359–362. doi: 10.1038/372359a0. PubMed DOI

Brass AL, et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008;319:921–926. doi: 10.1126/science.1152725. PubMed DOI

Krishnan L, et al. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase. J Virol. 2010;84:397–406. doi: 10.1128/JVI.01899-09. PubMed DOI PMC

Lee K, et al. Flexible Use of Nuclear Import Pathways by HIV-1. Cell Host Microbe. 2010;7:221–233. doi: 10.1016/j.chom.2010.02.007. PubMed DOI PMC

Price AJ, et al. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS pathogens. 2012;8:e1002896. doi: 10.1371/journal.ppat.1002896. PubMed DOI PMC

Bushman FD, et al. Host Cell Factors in HIV Replication: Meta-Analysis of Genome-Wide Studies. PLoS pathogens. 2009;5:e1000437. doi: 10.1371/journal.ppat.1000437. PubMed DOI PMC

Konig R, et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell. 2008;135:49–60. doi: 10.1016/j.cell.2008.07.032. PubMed DOI PMC

Campbell EM, Hope TJ. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 2015;13:471–483. doi: 10.1038/nrmicro3503. PubMed DOI PMC

Stremlau M, et al. The cytoplasmic body component TRIM5 alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004;427:848–853. doi: 10.1038/nature02343. PubMed DOI

Stremlau M, et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5 alpha restriction factor. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:5514–5519. doi: 10.1073/pnas.0509996103. PubMed DOI PMC

Price AJ, et al. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS pathogens. 2014;10:e1004459. doi: 10.1371/journal.ppat.1004459. PubMed DOI PMC

Rasaiyaah J, et al. HIV-1 evades innate immune recognition through specific cofactor recruitment. Nature. 2013;503:402. doi: 10.1038/nature12769. PubMed DOI PMC

Francis AC, Melikyan GB. Single HIV-1 Imaging Reveals Progression of Infection through CA-Dependent Steps of Docking at the Nuclear Pore, Uncoating, and Nuclear Transport. Cell Host Microbe. 2018;23:536–548.e536. doi: 10.1016/j.chom.2018.03.009. PubMed DOI PMC

Burdick RC, et al. Dynamics and regulation of nuclear import and nuclear movements of HIV-1 complexes. PLoS pathogens. 2017;13:e1006570. doi: 10.1371/journal.ppat.1006570. PubMed DOI PMC

Matreyek KA, Engelman A. The requirement for nucleoporin NUP153 during human immunodeficiency virus type 1 infection is determined by the viral capsid. J Virol. 2011;85:7818–7827. doi: 10.1128/JVI.00325-11. PubMed DOI PMC

Hilditch L, Towers GJ. A model for cofactor use during HIV-1 reverse transcription and nuclear entry. Current opinion in virology. 2014;4:32–36. doi: 10.1016/j.coviro.2013.11.003. PubMed DOI PMC

Hulme AE, Perez O, Hope TJ. Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci USA. 2011;108:9975–9980. doi: 10.1073/pnas.1014522108. PubMed DOI PMC

Mamede JI, Cianci GC, Anderson MR, Hope TJ. Early cytoplasmic uncoating is associated with infectivity of HIV-1. Proc Natl Acad Sci USA. 2017;114:E7169–E7178. doi: 10.1073/pnas.1706245114. PubMed DOI PMC

Lukic Z, Dharan A, Fricke T, Diaz-Griffero F, Campbell EM. HIV-1 uncoating is facilitated by dynein and kinesin 1. J Virol. 2014;88:13613–13625. doi: 10.1128/JVI.02219-14. PubMed DOI PMC

Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol. 2005;79:15567–15572. doi: 10.1128/JVI.79.24.15567-15572.2005. PubMed DOI PMC

Xu H, et al. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology. 2013;10:70. doi: 10.1186/1742-4690-10-70. PubMed DOI PMC

Dick RA, Mallery DL, Vogt VM, James LC. IP6 Regulation of HIV Capsid Assembly, Stability, and Uncoating. Viruses. 2018;10:640. doi: 10.3390/v10110640. PubMed DOI PMC

Dick RA, et al. Inositol phosphates are assembly co-factors for HIV-1. Nature. 2018;560:509–512. doi: 10.1038/s41586-018-0396-4. PubMed DOI PMC

Mallery, D. L. et al. IP6 is an HIV pocket factor that prevents capsid collapse and promotes DNA synthesis. Elife7, 10.7554/eLife.35335 (2018). PubMed PMC

Ambrose Z, Aiken C. HIV-1 uncoating: connection to nuclear entry and regulation by host proteins. Virology. 2014;454-455:371–379. doi: 10.1016/j.virol.2014.02.004. PubMed DOI PMC

Rumlova, M. & Ruml, T. In vitro methods for testing antiviral drugs. Biotechnol Adv, 10.1016/j.biotechadv.2017.12.016 (2017). PubMed PMC

Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol. 2002;76:5667–5677. doi: 10.1128/JVI.76.11.5667-5677.2002. PubMed DOI PMC

Shah, V. B. & Aiken, C. In vitro uncoating of HIV-1 cores. J Vis Exp, 10.3791/3384 (2011). PubMed PMC

Yang Y, Luban J, Diaz-Griffero F. The fate of HIV-1 capsid: a biochemical assay for HIV-1 uncoating. Methods Mol Biol. 2014;1087:29–36. doi: 10.1007/978-1-62703-670-2_3. PubMed DOI PMC

Fricke T, Diaz-Griffero F. HIV-1 Capsid Stabilization Assay. Methods Mol Biol. 2016;1354:39–47. doi: 10.1007/978-1-4939-3046-3_3. PubMed DOI PMC

Fricke T, Brandariz-Nunez A, Wang X, Smith AB, III, Diaz-Griffero F. Human cytosolic extracts stabilize the HIV-1 core. J Virol. 2013;87:10587–10597. doi: 10.1128/JVI.01705-13. PubMed DOI PMC

Bharat, T. A. M. et al. Cryo-electron microscopy of tubular arrays of HIV-1 Gag resolves structures essential for immature virus assembly. Proceedings of the National Academy of Sciences, 10.1073/pnas.1401455111 (2014). PubMed PMC

Hadravova R, Rumlova M, Ruml T. FAITH - Fast Assembly Inhibitor Test for HIV. Virology. 2015;486:78–87. doi: 10.1016/j.virol.2015.08.029. PubMed DOI

Ulbrich P, et al. Distinct roles for nucleic acid in in vitro assembly of purified Mason-Pfizer monkey virus CANC proteins. J Virol. 2006;80:7089–7099. doi: 10.1128/JVI.02694-05. PubMed DOI PMC

Campbell S, Vogt VM. Self-Assembly In-Vitro of Purified Ca-Nc Proteins from Rous-Sarcoma Virus and Human-Immunodeficiency-Virus Type-1. Journal of Virology. 1995;69:6487–6497. PubMed PMC

von Schwedler UK, Stray KM, Garrus JE, Sundquist WI. Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein. J Virol. 2003;77:5439–5450. doi: 10.1128/JVI.77.9.5439-5450.2003. PubMed DOI PMC

Fuzik T, Ulbrich P, Ruml T. Efficient Mutagenesis Independent of Ligation (EMILI) J Microbiol Methods. 2014;106:67–71. doi: 10.1016/j.mimet.2014.08.003. PubMed DOI

Blair WS, et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS pathogens. 2010;6:e1001220. doi: 10.1371/journal.ppat.1001220. PubMed DOI PMC

Bhattacharya A, et al. Structural basis of HIV-1 capsid recognition by PF74 and CPSF6. Proc Natl Acad Sci USA. 2014;111:18625–18630. doi: 10.1073/pnas.1419945112. PubMed DOI PMC

Shi J, Zhou J, Shah VB, Aiken C, Whitby K. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol. 2011;85:542–549. doi: 10.1128/JVI.01406-10. PubMed DOI PMC

Gross I, Hohenberg H, Krausslich HG. In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. Eur.J.Biochem. 1997;249:592–600. doi: 10.1111/j.1432-1033.1997.t01-1-00592.x. PubMed DOI

Fricke T, Buffone C, Opp S, Valle-Casuso J, Diaz-Griffero F. BI-2 destabilizes HIV-1 cores during infection and Prevents Binding of CPSF6 to the HIV-1 Capsid. Retrovirology. 2014;11:120. doi: 10.1186/s12977-014-0120-x. PubMed DOI PMC

Rankovic, S., Ramalho, R., Aiken, C. & Rousso, I. PF74 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced Uncoating. J Virol92, 10.1128/JVI.00845-18 (2018). PubMed PMC

Singh K, et al. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019;10:1227. doi: 10.3389/fmicb.2019.01227. PubMed DOI PMC

Rumlova, M., Krizova, I., Zelenka, J., Weber, J. & Ruml, T. Does BCA3 Play a Role in the HIV-1 Replication Cycle? Viruses10, 10.3390/v10040212 (2018). PubMed PMC

Dostalkova, A. et al. Mutations in the basic region of the Mason-Pfizer monkey virus nucleocapsid protein affect reverse transcription, gRNA packaging and the site of viral assembly. J Virol, 10.1128/JVI.00106-18 (2018). PubMed PMC

Humpolickova J, Mejdrova I, Matousova M, Nencka R, Boura E. Fluorescent Inhibitors as Tools To Characterize Enzymes: Case Study of the Lipid Kinase Phosphatidylinositol 4-Kinase IIIbeta (PI4KB) J Med Chem. 2017;60:119–127. doi: 10.1021/acs.jmedchem.6b01466. PubMed DOI

The Present and Future of Virology in the Czech Republic-A New Phoenix Made of Ashes?

Targeting the Virus Capsid as a Tool to Fight RNA Viruses

Fullerene Derivatives Prevent Packaging of Viral Genomic RNA into HIV-1 Particles by Binding Nucleocapsid Protein

In Vitro Quantification of the Effects of IP6 and Other Small Polyanions on Immature HIV-1 Particle Assembly and Core Stability

PF74 and Its Novel Derivatives Stabilize Hexameric Lattice of HIV-1 Mature-Like Particles